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Abstract: Endometrial cancer (EC) is the most common malignancy of the genital tract among women in
developed countries. Recently, a molecular classification of EC has been performed providing a system
that, in conjunction with histological observations, reliably improves EC classification and enhances
patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool
for translational research, since they closely resemble patient tumour features and retain molecular and
histological features. In EC, PDX models have already been used, mainly as an individualized approach
to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their
uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC
network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour
and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and
represent an excellent reservoir of EC tumour samples for translational research. This review compiles the
information on current methods of EC PDX generation and their utility and provides new perspectives
for the exploitation of these valuable tools in order to increase the success ratio for translating results to
clinical practice.
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1. Introduction
1.1. Cancer Models
Establishing suitable models is one of the cornerstones for cancer research. Among the most
important and challenging are mouse models, since they have to mimic different steps of the disease
and are used as tools for biomarker identification as well as preclinical models for therapy drug
screening [1,2]. In the last 60 years, murine cancer models have evolved from cell-line-derived to
genetically engineered mice (GEM) and tissue allo- or xeno-graft models [3,4]. The main differences
among these models are the genetic similarity between tumours and the host (isogenic, allogenic,
or xenogenic); the site of tumour injection, implantation, growth, and development (heterotopic
versus orthotopic); and the immunological status or immunocompetence of the host. Although
cell-line-derived and GEM models have led to significant advances in cancer biology and are still
crucial for cancer research [5], they often fail to recapitulate key aspects of human malignancies and
thus do not adequately predict drug effects in the clinic. In fact, the high failure rate of preclinical
compounds in clinical trials clearly demonstrates the limitations of existing preclinical models [6,7].
Thus, there is an urgent need to develop more realistic and clinically relevant mice models that reliably
represent the patient‘s tumour according to its genetic and molecular profile, its histopathology,
the disease course and metastatic progression profile, and the therapy response [8]. The satisfaction of
all these criteria will result in models with a close resemblance to human disease, enabling their use in
preclinical trials with a high predictive value and significance for transferring results into the clinic.
In this context, patient-derived xenograft (PDX) models have emerged as an excellent alternative to
overcome these shortcomings [9,10]. PDX development is based on transplanting fresh cancer patient
tissue samples directly into immunocompromised mice. In short, tumour tissue obtained directly from
the operating room or from a biopsy is sliced into small fragments or disaggregated into cell suspension
and surgically implanted or inoculated into immunocompromised mice. The most common mice
strains used are SCID, NOD/SCID, NSG, and athymic nude mice [11]. The implantation or injection
of the tumour fragment could be performed heterotopically or orthotopically. Tumours typically
engraft over the course of weeks to months, depending mainly on tumour features (stage, grade,
and aggressiveness). Upon engraftment and during exponential growth, the tumour is harvested and
prepared for transplantation into one or various animals to develop a mice cohort of PDX that could
be used for molecular characterization, biobanking, or as preclinical models. Serial expansions can
take place for several passages maintaining tumour genetic fidelity [10,12].
As we have mentioned before, some research prefers to use tumour tissue fragments for PDX
development, while other research uses a tumour cell suspension as the starting material. Each method
has its advantages and disadvantages; tumour fragments retain cell–cell interactions as well as
conserve tissue architecture, therefore mimicking better the tumour microenvironment. Alternatively,
a single-cell suspension is a more heterogeneous sample that would represent unbiasedly the whole
tumour; however, to obtain this type of sample, it is necessary to chemically or mechanically process
the tissue, which affects cell viability and has the risk of decreasing engraftment success [13]. Also,
the tumour implantation site is a crucial issue for PDX development. Heterotopic implantation occurs
when the tumour fragment is implanted into an area of the mouse unrelated to the original tumour site,
generally subcutaneously, in the interescapular region, the mammary fat pad, or the sub-renal capsular
site. In contrast, orthotopical transplantation refers to when the patient’s tumour tissue is put into the
corresponding anatomical organ as the original primary tumour. Subcutaneous PDX rarely develop
metastases in mice and it is difficult to use them to simulate the initial tumour microenvironment.
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In contrast, orthotopic models can mimic the natural environment of a primary tumour, turning it into
an ideal model to study the metastatic process. Nevertheless, these models can be difficult to generate
depending on the organ of implantation [14].
In summary, the main features and advantages of PDX models are: (1) preservation of the genetic
profile of the primary tumour and stability along passages into several animals; (2) retention of the
histological and phenotypic features of the tumour, such as its tissue architecture, and the maintenance
of stromal and stem cell components, cell-to-cell interactions, and spatial distribution; (3) amplification
of tumour tissue biomass to facilitate tumour biology analysis, such as tumour characterization and
biomarker identification; and (4) generation of a mice cohort with the same tumour that can be used as
a preclinical model to test and predict anticancer drug response [15].
1.2. Endometrial Cancer
Endometrial cancer (EC) is the most common gynaecological cancer in developed countries and
the sixth in mortality among all cancer types in women [16]. The majority of ECs are diagnosed at
early stages when the tumour is still confined to the uterus and are frequently associated with vaginal
bleeding as an initial symptom [17–19]. EC early detection is crucial to increase patient survival: the
5-year overall survival rate is around 80–95% in early stage tumours and falls to 20–60% in more
advanced tumours [20,21].
Classically, EC has been classified into a dualistic model according to its biological, molecular,
and clinical features. Type I or endometrioid endometrial carcinomas, comprising 80% of cases,
are mainly represented by low-grade and hormone-receptor-positive tumours, while type II or
non-endometrioid endometrial carcinomas are represented by papillary serous carcinoma, clear cell
carcinoma, and carcinosarcoma, among other minor histologies, and are characterized by high-grade
tumours and loss of hormone receptors [22–26]. Although serous, clear cell, and carcinosarcoma
histologies represent only 10–15% of all EC cases, these minority subtypes account for up to 40% of all
EC-related recurrences and subsequent deaths. This lower survival rate in comparison to endometrioid
EC tumours is due, despite the fact that a growing list of evidence indicates the distinct nature of these
subtypes at the molecular and clinical level, to non-endometrioid EC subtypes still being managed
with the same adjuvant treatment as endometrioid EC tumours [27]. Similarly, the International
Federation of Gynaecology and Obstetrics (FIGO) established a stratification system of EC according
to its risk of recurrence based on postoperative pathologic information, such as histologic type, tumour
grade, stage, and myometrial and lymphovascular invasion [26]. Nonetheless, 8% to 10% of early stage
endometrial carcinoma develops recurrence and distant metastasis. Current classification systems have
a limited potential to predict recurrence of EC patients, hence the need for more reliable systems to
categorize and classify EC tumours to better tailor the clinical management of each individual patient.
Recently, the Cancer Genome Atlas Network (TCGA) performed an integrated genomic, transcriptomic,
and proteomic analysis focusing on endometrioid EC and serous histologies, demonstrating that
EC is a heterogenic disease. The TCGA identified and classified EC into four distinct molecular
subgroups: POLE ultramutated (DNA polymerase epsilon), microsatellite instability hyper mutated,
copy-number-low microsatellite stable, and copy-number-high serous-like [28]. Interestingly, TCGA
molecular characterization data demonstrated that a quarter of the tumours classified by the dualistic
model, as high-grade endometrioid EC, have a molecular phenotype similar to Type II serous
non-endometrioid EC, including frequent TP53 mutations and extensive somatic copy number
alterations (SCNA), thus suggesting that among these subtypes of patients similar clinical management
should be considered beyond the histological classification. The molecular classification of EC has
shown great promise, proving to be reproducible, demonstrating a higher association with clinical
outcomes, and providing more valuable prognostic and predictive information in comparison to the
dualistic classification system.
Considering that, researchers and clinicians are now enthusiastic and believe that a combination
of both classification systems would be promising to precisely classify EC, thus improving the
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management of EC patients. However, the road to an ideal scenario should still be paved with
a deeper understanding of the ability to predict treatment-response and with an increased variety of
effective therapeutic options for the different types of EC. Moreover, inter and intra-tumour genetic
heterogeneity represents a challenge that should be faced in the current classification systems as this
might have implications for the response to standardized or personalized treatments [29]. In this sense,
the development of clinical relevant models for translational research is of great importance, since they
represent the disease and could translate the beneficial results of preclinical trial and drug screening
assays into clinics to improve EC treatment therapy.
2. Endometrial Cancer PDX Models
2.1. Strategies for EC PDX Model Development
Even though PDX development is widely described [10,30], several steps may differ across
different research groups regarding EC PDX development. In this review, which is co-authored by
European Network of Individual Treatment in Endometrial Cancer (ENITEC) members, we analyze
strategies for PDX model development and provide an overall perspective on the value of PDX models
for EC research.
Cabrera et al. was the first to describe the development of orthotopic PDX models using
human EC tumour tissue [31]. To develop this model, tumour tissue resected from an EC tumour
was grown subcutaneously in nude mice previously to orthotopic implantation. Once the tumour
engrafted subcutaneously, tumour was removed, mechanically crumbled, and injected transvaginally
or transmyometrially into nude mice, generating the orthotopic PDX models. Between the two different
methods for orthotopic PDX model generation, the transmyometrial implantation of the tumour had
a higher engraftment rate compared to the tranvaginal injection. They showed that orthotopically
implanted tumours produced myometrial infiltration, lymph-vascular invasion, and dissemination in
the pelvic cavity. In addition, tumours retained the molecular and histological characteristics of the
original samples, reproducing glandular patterns and expressing hormone receptors.
Similarly, Haldorsen et al. [32] reported the development of an orthotopic PDX by mechanical
dissociation of a primary tumour biopsy into a cell suspension, which was injected into the left uterine
horn of NSG mice. Unlike Cabrera et al., in which PDX models have to be euthanized after 63 days as
a consequence of tumour invasion, presence of pelvic mass, and ascites development, Haldorsen et al.
showed that their PDX developed from a cellular suspension took longer to reach this phenotype:
almost 10 months. However, they showed that their orthotopically grown tumours could be excised,
disaggregated into a cell suspension, and reinjected to develop a next-generation cohort of orthotopic
PDX mouse models.
Later on, Depreeuw et al. [33] developed and fully characterized a panel of 24 subcutaneous
EC PDX models that includes more frequent histologic and genetic subtypes of EC. The authors
demonstrated that EC PDX models can be successfully established from both primary, metastatic,
and recurrent endometrioid EC and non-endometrioid EC tumours, with an overall engraftment rate
of 60%. They also showed that these models closely resemble the tissue architecture and genomic
features of the original human tumours. By whole-exome sequencing focused on cancer consensus
genes, they found that most of the mutations were common between the primary human tumour and
its paired PDX model in four cases. In addition, they evaluated genomic copy number alteration in
both samples and found that, on average, 90% of the genome had the same copy number alterations
between the primary tumour and the xenograft. Similarly, by immunohistochemistry staining of
PDX and a primary sample with a human vimentin antibody, they showed that human EC stroma is
replaced by murine stroma after engraftment.
On the other hand, Unno et al. [34] established a xenograft model by transplanting fragments of
four different EC histologies, from patients undergoing surgery, into the renal capsule of NSG mice.
Following this approach, the authors reported that tumour xenografts retain characteristics of the
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original tumour and display features that are unique to endometrioid EC or non-endometrioid EC.
In addition, they showed that each model has a different invasive and metastatic capacity according
to its histology as well as a distinct dependence on β-estradiol [34]. Despite the technical difficulties
presented by this type of approach, a renal capsule xenograft model is suitable for studying aggressive
EC since tumour cells are in an environment susceptible to invasion and metastasis.
Recently, Pauli et al. [35] described the development of PDX from patient-derived tumour
organoids (PDTOs). The authors collected metastatic and primary tumours from 18 different
tumour types (two EC) and established culture organoids characterized by cytology and histology.
Once established, PDTOs were subcutaneously injected into the flanks of nude mice. The xenograft
take rate varied from 2 weeks to 16 weeks based on tumour type, and they reported an 86.4%
engraftment rate of the PDTOs. They found that PDTOs and PDXs had similar histopathology
to the parental tumours from which they were derived. The whole-exome sequencing genetic profile
and single nucleotide variants analysis of PDTOs and PDXs showed excellent concordance with the
patient’s tumour.
2.2. Strategies for EC PDX Model Monitoring
The ability to monitor disease development is one of the major challenges when using mouse
models. Tumour xenografts growing subcutaneously could be followed simply by visual inspection
or palpation; however, the monitoring of orthotopic tumour xenografts requires the utilization of
imaging techniques to follow-up tumour progression. In this section, we will summarize the most
commonly used in vivo imaging techniques that are currently available to monitor tumour growth in
PDX models. A full description of these techniques is reviewed by Dall’Ara et al. [36].
• Micro-computed tomography is a high image resolution technique with great potential for in vivo
use since it could be coupled with other imaging modalities providing three-dimensional (3D)
reconstruction of bone and soft tissue. It has been used to study bone metastases [37] in mice and
also has been applied to monitor the progression of lung and liver tumours [38–40].
• Magnetic resonance imaging (MRI) also offers in-vivo, non-invasive, 3D, and high-resolution
images. In recent years, MRI has gained great importance due to the absence of ionizing radiation
and its soft tissue contrast. Hence, MRI is used not only for its ability to define lesions with
great spatial resolution but also to recover quantitative features that might be able to predict
cancer progression.
• Positron emission tomography (PET) is a highly sensitive and specific imaging technique used
to visualize the distribution and concentration of radiolabelled molecules injected into murine
models. It is a form of quantitative whole-body imaging used for the in vivo monitoring of
biological processes, such as enzymatic reactions, cellular metabolism, and cell proliferation and
migration [41], which makes it an ideal tool for the imaging of cancer [32,42].
• Single-Photon Emission Computed Tomography is a technique that detects gamma radiation
directly emitted by a radionuclide during decay and provides 3D information by acquiring
multiple two-dimensional (2D) images while rotating around the imaged object. This technique is
frequently used in oncology to visualize neuroendocrine tumours [43] and thyroid cancer [44,45]
and to perform bone scintigraphy.
• Ultrasound is an ideal technique for detecting tumour growth in mice since it produces
high-resolution images of small structures. It is a non-ionizing radiation technique, portable, easy
to use, and quickly generates relevant images.
• Intravital microscopy is an optical imaging technique that enables highly sensitive in vivo imaging
of tissue structure and function at high spatial resolution (cellular and sub-cellular) and temporal
resolution. However, a surgical procedure is required to access the tissue/organ of interest
for microscopy, having therefore the consequence that immediately after image acquisition
the animal must be sacrificed. Intravital microscopy has been reported to be used in studies
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involving a metastatic process [46,47] and the response of tumour blood vessels to vascular
targeted therapy [48,49].
• Whole-body optical imaging is a sensitive technique based on fluorochromes excitation by an
external light source (fluorescence) or by chemiluminescent enzymatic light emission reactions
within the animal (bioluminescence). Despite the poor spatial resolution due to light scattering,
this technique enables the integration of the light signal emitted to obtain a 2D planar image.
Green fluorescence protein (GFP) has been widely used to measure in vivo tumour growth as
well as the effect of metastatic spread and drug treatments on different types of cancer in mouse
models [50,51].
Recently, Haldorsen et al. [32] described the use of a multimodal imaging platform based on a
PET/CT scan and MRI in orthotopic EC cell-line-derived xenografts and PDX models and compared
its relevance to bioluminescence imaging (BLI). In this study, they managed to monitor tumour growth,
progression, and metastasis spread. Their findings bring forward the value of imaging techniques in
the follow-up of orthothopic EC PDX models. Nevertheless, much research is needed to potentiate the
use of imaging techniques for the follow-up of orthotopic EC PDX models. A comparative image of
BLI and a PET/CT assay in mice models is shown in Figure 1.
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Catalan of Oncology (IDIBELL-ICO), and the Vall d’Hebron Institute of Research (VHIR) in order to 
compile the information on EC PDX models available within this network. Altogether, we have 
generated a stable cohort of PDX models from primary tumour and metastasis from 124 EC patients 
recruited in different centres across Europe. This represents one of the most extensive and best-
characterized EC PDX model cohorts available for research and is continuously increasing since we 
are generating new models from EC patients (Table 1). 
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2.3. Collaborative EC PDX Cohort
In a collaborative effort within the ENITEC consortium, we here describe in detail the PDX
mouse cohort developed by the groups in Katholieke Universiteit (KU) Leuven, Haukeland University
Hospital Bergen (HUHB), the Institute of biomedical research from Bellvitge–Institute Catalan of
Oncology (IDIBELL-ICO), and the Vall d’Hebron Institute of Research (VHIR) in order to compile the
information on EC PDX models available within this network. Altogether, we have generated a stable
cohort of PDX models from primary tumour and metastasis from 124 EC patients recruited in different
centres across Europe. This represents one of the most extensive and best-characterized EC PDX model
cohorts available for research and is continuously increasing since we are generating new models from
EC patients (Table 1).
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Table 1. PDX models developed by European Network of Individual Treatment in Endometrial Cancer (ENITEC) consortium members.
Research
Centre Type of Sample Type of PDX Tissue Engraftment Rate & Time Mouse Strain
Number
Models Type of Models Preclinical Drug Tested
IDIBELL-ICO Primary tumor,metastases orthotopic small tissue fragment 75–90% 1–5 months Athymic nude 64
60%EEC; 10%PS; 20%CS; 3%CC;
7%other types Sorafenib, Chloroquine (61)
VHIR Primary tumor,metastases, recurrences heterotopic (s.c)
5–10 mm3
tissue fragment
60–80% 2–3 months Athymic nude 40 43%EEC; 32%PS; 10%CS; 2.5%CC;5%undifferentiated 7.5%other types
Carboplatin Paclitaxel,
Palbociclib (60)
KUL Primary tumor,metastases, recurrences heterotopic (s.c)
8–10 mm3
tissue fragment
100% 3–5 months Athymic nude 15 46%EEC; 13%PS; 13%CS;7%undifferentiated 21%other types
Carboplatin, NVP-BEZ235,
AZD 6244 (33)
HUHB Primary tumor,metastases orthotopic Cell suspension 25–100% 3–13 months NSG 5
60%EEC; 20%PS;
20%undifferentiated
IDIBELL-ICO: Institute of biomedical research from Bellvitge–Institute Catalan of Oncology; VHIR: Vall d’Hebron Institute of Research; KUL: Katholieke Universiteit Leuven; HUHB:
Haukeland University Hospital; EEC: Endometrioid endometrial cancer; PS: Papillary serous carcinoma; CS: Carcinosarcoma; CC: Clear cell carcinoma; s.c: Subcutaneous.
Int. J. Mol. Sci. 2018, 19, 2431 8 of 17
We have developed a heterogenous population of PDX covering almost every stage and grade of
both EC histological subtypes. In particular, we have 63 endometrioid and 56 non-endometrioid EC
PDX models, in which serous and carcinosarcoma histologies are the best represented with 22 and 19
models, respectively. Regarding staging, 62% of the endometrioid EC PDX models are represented by
FIGO stage I and classified according to Morice et al. [25] as low to intermediate risk of recurrence,
while the rest of the endometrioid EC PDX models are represented by advanced stage III (21%) and
stage IV (3%) tumours classified as high risk. Among the non-endometrioid EC PDX models, almost
60% are advanced tumours represented by FIGO stages III and IV, whilst 32% of the models are early
stage tumours (Table 1). Analysing in depth our data, we observed that approximately the same
number of PDX models were developed from both histologies, showing that endometrioid EC and
non-endometrioid EC tumours could grow as PDX. Similarly, we do not observe a trend towards the
specific growth of any EC tumour subtype (Table 2).
Our PDX cohort was developed both by heterotopic transplantation of fresh tumour tissue
fragments recollected from a surgery room and implanted subcutaneously into athymic nude mice and
by orthotopic implantation throughout a laparotomic incision. The engraftment rate of subcutaneous
EC PDX varied from 60–80%; however, once the tumour was developed, the engraftment rate increased
to nearly 100% in subsequent passages. In addition, PDX models take approximately 3–5 months
to engraft and develop the first generation, while subsequent passages take less time to engraft and
progress. In contrast, the orthotopic PDX model engraftment rate varies from 75–90% and also takes
2–5 months to develop a palpable and transferable tumour. Additionally, a small cohort of five
tumours from EC patients was also injected orthotopically into the left uterine horn of NSG mice.
In this case, a primary tumour sample is manually dissociated, filtered, and centrifugated and then
a cell suspension is injected by laparotomy in a 1:1 proportion with Matrigel [32]. For this type of
model, the engraftment rate is lower, ranging from 25 to 100% in the first generation, and the time of
engraftment is also slower: it takes on average 10 months to develop an orthotopic EC PDX model.
Table 2. ENITEC PDX models classified according to histology, stage, and differentiation grade.
Endometrioid EC Non-Endometrioid EC
FIGO stage
I 39 62% 18 32%
II 7 11% 4 7%
III 13 21% 27 48%
IV 2 3% 5 9%
Grade
1 20 32%
2 23 37%
3 20 32% 56 100%
Histology
Serous carcinoma 22 39%
Carcinosarcoma 19 34%
Clear Cell carcinoma 4 7%
Others 11 20%
All of our models have been histologically characterized by H&E staining (Figure 2). Single-
nucleotide polymorphism fingerprints analysis as well as the identification of gene mutations have
been performed in some models. In the same way, we are working on the molecular characterization
of PDX tumours by whole-exome sequencing and on the classification of those tumours according
to the TCGA system. Finally, we have to mention that some of our PDX models have been used for
preclinical drug-testing studies, described in the following section, with excellent results mimicking
EC pathology and having a relevant response to treatment, demonstrating the high predictive value
that PDX models could have in EC research.
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EC patients. Panel G corresponds to a carcinosarcoma histology, and panel H corresponds to a serous
carcinoma. Magnification 20×.
2.4. Use of EC PDX Models in Preclinical Studies
Personalized medicine refers to the discipline focused on treating patients individually with
molecular-targeted therapies directed against the altered pathways of their own tumour. This is
expected to maximize treatment efficacy and minimize side effects [52]. Based on this notion, PDX
provides a powerful tool for personalized medicine as it retains the molecular profile of the individual
tumour. Similarly, many reports have shown that response rates in PDX correlate with those observed
in the clinic both for targeted agents and for classic cytotoxic drugs [53,54]. Thus, the potential for using
these models for directing individualized therapy in patients is being increasingly recognized [55].
In EC, the PI3K/AKT pathway is constitutively active due to mutations, and so this pathway has
been an attractive target for therapy in different EC preclinical studies. Winder et al. tested the effect
of MK2206, an allosteric inhibitor of AKT, on the growth and invasion of three EC PDX models grafted
under the renal capsule of NSG mice. They found that MK2206 treatment inhibited tumour growth
as well as decreased invasion into the kidney and spread throughout the peritoneum in the three
different types of PDX (endometrioid EC grade 2, endometrioid EC grade 3, and non-endometrioid
EC serous) [56]. Similarly, Yu et al. reported the use of two EC PDX models to study the effect of
a two-drug combination, which acts on AKT (ARQ092) and FGFR1/2 (ARQ087), to overcome AKT
inhibitor treatment loss of efficacy and resistance. FGFR is also frequently mutated in EC, promoting
tumour progression and treatment resistance. Based on this, they suggested that by combining AKT
and FGFR1/2 targeted therapy, they would be able to overcome the resistance mechanism. Even
though they had a synergistic effect in EC cell lines, they only obtained enhanced antitumour activity
in one of the PDX models compared to the single-agent treatment. However, the authors suggested
that it is necessary to define EC patient molecular signatures, i.e., with mutations of PIK3CA/PIK3R1
and FGFR, to design a suitable treatment strategy and predict patients’ response [57].
The use of palbociclib against the cyclin-dependent kinases CDK4 and CDK6 has successfully
been used in advanced breast cancer [58] and it is under evaluation in many other cancer types in
phase II and III clinical trials [59]. In EC, Dosil et al. [60] performed the first preclinical study to test the
therapeutic potential of palbociclib; specifically, this was tested in the endometrial malignancies driven
by Pten deficiency. This work started with the assessment of palbociclib response in vitro and in a
PTEN-deficient GEM model and was finally validated in a PTEN-mutated PDX model of endometrioid
EC of FIGO stage IIIC and grade 2. This work evidenced that palbociclib has therapeutic potential as
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an anticancer drug in the endometrium, since it reduces tumour cell proliferation and disrupts the
tumourigenesis process [60].
Similarly, Dupreeuw et al. [33] tested the efficacy of NVP-BEZ235 (a dual pan-PI3K/mTOR
inhibitor) and AZD6244 (an MEK1/2 inhibitor) in a PDX model harbouring a high-grade recurrent
endometrioid carcinoma carrying PTEN, PIK3CA, and KRAS mutations. They showed that the
treatment as a single therapy significantly reduced tumour growth compared to the control group.
Moreover, when combining both therapies, NVP-BEZ235 and AZD6244, the treatment was as effective
as Carboplatin, resulting in disease stabilization showing no increment of tumour growth.
All of the above-mentioned studies shared a similar approach to evaluating the efficacy of targeted
therapies in EC: all of them relied on the use of PDX to validate a specific treatment which was first
assessed in one or more in vitro and/or in vivo models. Moreover, PDX models could also be used
to identify pathways responsible for therapy-resistant mechanisms and to identify new approaches
to overcome any acquired resistance in EC tumours. Sorafenib, an antiangiogenic drug, has been
proposed as a promising targeted therapy for EC, but a multicentre phase II clinical trial demonstrated
moderate effects. In a recent work, Eritja et al. [61] studied the resistance mechanism of sorafenib in EC
and demonstrated that autophagy acted as a protective mechanism against sorafenib. They developed
in vitro assays and three different endometrial orthotopic xenografts (endometrioid EC grade 1, 2,
and 3), and observed that the inhibition of autophagy by using cloroquine potentiates sorafenib effects
in PDX orthotopic EC tumours. These results provided insights into the modest effects of sorafenib
trials in EC patients and might open new avenues for the design of preclinical studies using sorafenib.
Equally important is the discovery of biomarkers to predict treatment-response, as this will help to
tailor the treatment of EC patients. In this field, Groeneweg et al. [62] investigated the effectiveness of
HER2 inhibition in serous non-endometrioid EC. The combination of in vitro and in vivo cell-line and
PDX models permitted the authors to demonstrate that lapatinib as a single agent and in combination
with trastuzumab induced significant tumourstatic effects only in those tumours harboring HER2
gene amplification. In the non-amplified tumour xenografts, a complete lack of response to any
administered therapy was seen. Thus, this study unveiled that HER2 gene amplification might be
used a biomarker for response to HER2 inhibition in uterine serous carcinoma, as has been shown in
breast and gastric carcinomas. Similarly, in another study published by Groeneweg et al. [63], they
demonstrated that the expression of nuclear Notch1 could be associated with tumour progression since
it was expressed in a significant proportion of endometrioid ECs (12%) as well as in the majority of
serous non-endometrioid EC analysed (58%). They showed that treatment with the gamma-secretase
inhibitor MRK-003 decreased the proliferation of serous cell lines in vitro and restricted the growth of
xenografts derived from serous cell lines and primary human serous tissue in vivo. Moreover, MRK-003
treatment augmented the anti-tumour activity of standard Paclitaxel/Carboplatin (P/C) therapy in one
of the two primary human PDX models. The observed synergistic effect of MRK-003 with conventional
P/C therapy in one primary model provides pilot data to suggest that the combination of a Notch
inhibitor and standard chemotherapy may have promise in the management of serous carcinoma.
Based on these data, EC PDX models are currently playing an important role in defining new
therapeutic options for the different EC subtypes and helping in the selection of populations of patients
most likely to be sensitive to a new agent. However, all the studies performed up to date only include
from a single to a few EC PDX models; thus, the results are hard to translate into larger populations.
3. New Perspectives on the Use of EC PDX Models
There exist interesting avenues for the exploitation of PDX models, which have been explored
in other types of cancers but not in the field of EC research. A co-clinical trial is a concept, similar to
personalized PDX models, which is based on the development of a PDX from a patient enrolled in a
clinical trial and treated in the same way as the patient [30,64]. This strategy provides an interesting
platform for the identification of predictive or response biomarkers and on which to assess the
therapeutical benefit of novel combinations. Limitations of co-clinical trials include the limited ratio of
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engraftment of PDX models and the extended time for PDX development of particular cases, which
might impair the evaluation of the PDX response for all patients recruited in the clinical trial. Moreover,
PDX models do not always faithfully represent primary tumour heterogeneity and, in these cases, PDX
therapy response would not be relevant for the patient.
Another interesting approach is the use of PDX panels for preclinical studies as opposed to the
traditional methods of assessing drugs in just a few models [65,66]. This approach uses PDX models
as if those were patients participating in a phase II clinical trial, i.e., a cohort of different PDX models
covering different types and stages of cancer are used, and only one or a few animals with specific
characteristics are included per patient and receive a specific treatment. When analysing the responses
to treatments, it is not the response of an individual mouse/tumour that matters, but the population
response. It should be noted, however, that to completely capture the full inter-tumour heterogeneity of
a particular cancer type, large panels of PDX are needed to cover different subtypes, stages, and grades
of differentiation. Considering this, we have to mention that this approach is not feasible for tumour
types that poorly establish as xenograft models.
Migliardi et al. [65] was the first to describe this mouse clinical trial approach. Later on, Gao et al. [67]
proposed the use of just one tumour representing “a patient” to allow for even greater efficiency (the
1× 1× 1 approach), determining that using just the one animal per cohort study design has outstanding
reproducibility for the data collected. The utility of this approach is that it enables many more types of
PDX and treatment groups to be assessed operationally, and the inter-heterogeneity of patients can be
captured experimentally. This approach is closely related to a clinical study in patients and is being used
by some researchers and pharmaceutical companies motivated to increase the success rate of drugs tested
in preclinical phases that are finally approved by regulatory agencies.
4. Collaborative PDX Networks
At present, the cost and resources needed for PDX development and maintenance are a limiting
factor for many researchers in order to develop their own models. For this reason, to facilitate working
with PDX models, accessible collaborative networks between academic research groups have been
established that closely cooperate with the clinic in order to associate preclinical experimentation and
clinical activities. Such networks include the EurOPDX Consortium, the U.S. National Cancer Institute
(NCI) repository of patient-derived models, the U.S. Pediatric Preclinical Testing Consortium (PPTC),
the Children’s Oncology Group (COG) cell culture and xenograft repository, the Public Repository of
Xenografts (PRoXe), and the Novartis Institutes for Biomedical Research PDX Encyclopedia (NIBR
PDXE) [68]. Some of the PDX models developed in EC in the ENITEC consortium are included in the
EurOPDX network.
Besides academic collaborations, commercial companies have also started to provide PDX
models, such as The Jackson Laboratory (Bar Harbor, ME, USA), Xenopat (Barcelona, Spain),
CrownBio (Santa Clara, CA, USA), Oncotest GmbH (Freiburg, Germany), AVEO Oncology (Cambridge,
MA, USA), Living Tumour Laboratory (Vancouver, BC, Canada), Urolead (Strasbourg, France),
Experimental Pharmacology & Oncology Berlin-Buch GmbH (Berlin-Buch, Germany), and XenTech
(Paris, France) [69].
5. PDX-Related Challenges
Although EC PDX models have been established for almost a decade, there are still several
challenges that should be faced in the near future. First, immunocompromised mice are used so
as to not reject human tumour, meaning that immunologically related aspects cannot be taken into
account. Next, human stroma in mice is replaced by murine stroma over different generations.
This has been shown for different types of tumours, but also more specifically for EC [33]. Both
immunological and stromal cells are part of the tumour microenvironment, and it is known that they
are implicated in cancer progression and metastasis [70]. Therefore, there is a need to investigate the
tumour microenvironment [71]. Third, although tumour heterogeneity is maintained, only small pieces
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of primary tumours are used, which means there is potential for loss of tumour information. Indeed,
efforts to reproduce clear intra-tumour heterogeneity in different murine models should be addressed.
Finally, it is becoming clear that, although the pharmacological and most of the original biological
characteristics are maintained, tumours partially undergo mouse-specific evolution. More specifically,
Ben-David et al. monitored the SCNAs of 1110 PDX models for 24 cancer types over time. They did find
an accumulation of SCNAs over time that correlate with the primary tumour. However, several SCNAs
observed in primary tumours disappear in PDX models and SCNAs acquired by PDXs differ from
primary tumours [72]. Other studies suggest that, although there is indeed engraftment-associated
selection, the majority of changes do not occur in oncogenic drivers and are therefore not affecting
intra-tumour heterogeneity [33,68,73].
To overcome the lack of tumour microenvironment and immune cell interaction, humanized
mice can be used [74]. Humanized models can be used to investigate cancer stem cells amongst
other biological facets, such as tumour–microenvironment interactions and anti-tumour immune
responses, and they can be used in immunotherapy research [75]. For endometrial cancer, no reports
using humanized mice have been published yet. However, humanized mice have been successfully
established for haematological malignancies [75] and many types of cancer [74,75]. Different
methodologies can be used to generate humanized models; however, this subject exceeds the scope of
this article and excellent reviews about humanized models can be found in the literature [68,73,75].
6. Conclusions and Future Perspectives
Over the last few decades, there has been increasing interest in developing more realistic and
clinically relevant mouse models. In this context, PDX emerges as a promising preclinical mouse
model mainly because it faithfully retains patient tumour characteristics and behaviour. Importantly,
EC PDX models have already been used in an individualized approach to evaluate the efficacy of novel
therapies and to identify biomarkers to predict treatment-response. Together with the advances of
omics techniques, which allow us to increase our understanding of the molecular alterations of EC
tumours and dysregulated EC pathways, EC PDX models are now an untapped source to improve the
definition, consecution, and output of preclinical studies to increase the success ratio in further clinical
phases. In this review, we compiled the information on EC PDX models that have been described in
the literature and highlight the models that have been generated in the ENITEC consortium, from their
generation to their use, and identify new perspectives and limitations of those models.
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EC Endometrial cancer
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NCI National Cancer Institute
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